Proton pump inhibitors: An assessment of efficacy and safety

Formulary

Volumn 34, Issue 5, 1999, Pages 437-451

  Chen, Bonnie P ^a,b   Chow, Moses S S ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; THEOPHYLLINE; WARFARIN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; ESOPHAGITIS; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; REVIEW; STOMACH ULCER; ZOLLINGER ELLISON SYNDROME;

EID: 0032973604     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Langtry HD, Wilde MI. Omeprazole: A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal antiinflammatory drugs. Drugs 1998;56:447-86.
2. 2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: A metaanalysis. Eur J Gastroenterol Hepatol 1995; 7:467-75.
3. Bianchi Porro G, Pace F, Peracchia A, et al. Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. J Clin Gastroenterol 1992;15:192-8.
4. Hill ADK, O'Donoghue DP. Omeprazole in refractory reflux oesophagitis. Gullet 1991;1:81-3.
5. Bate CM, Crowe JP, Dickinson RJ, et al. Reflux oesophagitis resolves more rapidly with omeprazole 20 mg once daily than with ranitidine 150 mg twice daily: Omeprazole 40 mg once daily provides further benefit in unresponsive patients. Br J Clin Res 1991;2:133-48.
6. Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1991;36:394-404.
7. Spencer CM, Faulds D. Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994;48:404-30.
8. Ekström P, Carling L, Unge P, et al. Lansoprazole versus omeprazole in active duodenal ulcer: A double-blind, randomized, comparative study. Scand J Gastroenterol 1995;30:210-5.
9. Petite JP, Slama JL, Licht H, et al. Lansoprazole vs omeprazole in the treatment of duodenal ulcer: A multicenter double-blind comparative trial. Gastroenterol Clin Biol 1993;17:334-40.
10. Florent C, Audigier JC, Boyer J, et al. Efficacy and safety of lansoprazole in the treatment of gastric ulcer: A multicentre study. Eur J Gastroenterol Hepatol 1994;6:1135-9.
11. Corallo J, Vicari F, Forestier S, Joubert M. Lansoprazole in acute treatment of reflux esophagitis [abstract]. Gastroenterology 1993;104:A58.
12. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996;91:1749-57.
13. Ramdani A, Paul G, Ruszniewski P, et al. Comparative efficiency of lansoprazole and omeprazole on 24-hour intragastric pH measurement in 9 cases of Zollinger-Ellison syndrome [abstract]. Gastroenterology 1992;103:A151.
14. Joelson S, Joelson I-B, Lundborg P, et al. Safety experience from long-term treatment with omeprazole. Digestion 1992;51(Suppl 1):93-101.
15. Koop H. Review article: Metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992;6:399-406.
16. Pounder R, Smith J. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 1990;19:141-53.
17. Wolfe MM, Soll AH. The physiology of gastric acid secretion. N Engl J Med 1988; 319:1707-15.
18. Modlin IM, Tang LH. The gastric enterochromaffin-like cell: An enigmatic cellular link. Gastroenterology 1996;111:783-810.
19. McCloy RF, Arnold R, Bardhan KD, et al. Pathophysiological effects of long-term acid suppression in man. Dig Dis Sci 1995;40(Feb Suppl):96S-120S.
20. Creutzfeldt W, Lamberts R. Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. Digestion 1992;51(Suppl 1): 76-81.
21. Lamberts R, Creutzfeldt W, Strüber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993;104:1356-70.
22. Kuipers EJ, Lee A, Klinkenberg-Knol EC, Meuwissen SGM. Review article: The development of atrophic gastritis - Helicobacter pylori and the effects of acid suppressive therapy. Aliment Pharmacol Ther 1995;9:331-40.
23. Fass R, Rosen HR, Walsh JH. Zollinger-Ellison syndrome: Diagnosis and management. Hosp Pract 1995;30:73-80.
24. Eissele R, Brunner G, Fischer B, et al. Evaluation of enterochromaffin-like (ECL) cell hyperplasia during long-term treatment with the proton pump inhibitor lansoprazole [abstract]. Gastroenterology 1993;104: A74.
25. Dekkers CP, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of active gastric ulcer - a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1998;12: 789-95.
26. Cloud ML, Enas N, Humphries TJ, Bassion S, and the Rabeprazole Study Group. Rabeprazole in treatment of acid peptic diseases: Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998; 43:993-1000.
27. Jaspersen D, Diehl KL, Schoeppner H, et al. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Aliment Pharmacol Ther 1998;12:49-52.
28. Pazzi P, Scagliarini R, Gamberini S, et al. Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. Aliment Pharmacol Ther 1998;12:731-4.
29. Adamek RJ, Pfaffenbach B, Szymanski C. Cure of Hpylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics. Helicobacter 1998;3:206-11.
30. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28.
31. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Scand J Gastroenterol 1993;28:224-8.
32. Spinzi GC, Bierti L, Bortoli A, et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998;12:433-8.
33. Fennerty MB, Kovacs TO, Krause R, et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med 1998; 158:1651-6.
34. Schwartz H, Krause R, Sahba B, et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: A randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol 1998; 93:584-9.
35. Lamouliatte H, Cayla R, Zerbib F, et al. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: Results of a prospective randomized open study. Am J Gastroenterol 1998;93:1531-4.
36. Bayerdörffer E, Mannes GA, Sommer A, et al. High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. Eur J Gastroenterol Hepatol 1992;4:697-702.
37. Brunner G, Harke U. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1994;8(Suppl 1):59-64.
38. 2-blocker-resistant esophagitis. Dig Dis Sci 1991;36:552-7.
39. Dent J, Yeomans ND, MacKinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis: A controlled double-blind trial of their efficacy and safety. Gut 1994;35:590-8.
40. Hallerback B, Unge P, Carling L, et al. The Scandinavian Clinics for United Research Group. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994;107:1305-11. F